Physician profile
Mary Theresa V Ladd
NPI 1649618786
$54,144.08
in general payments reported to CMS, 2019-2025
23 companies · $7,619 in 2025
The $7,619 reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $130 · 2021: $5,915 · 2022: $15K · 2023: $13K · 2024: $13K · 2025: $7,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $2,666 · Travel and Lodging: $43.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,625.00 |
| Food and Beverage | $2,665.66 |
| Travel and Lodging | $43.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25,511.43 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $23,615.29 | 2020-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $2,762.65 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $541.79 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $306.01 | 2019-2022 | |
| Almatica Pharma LLC | $225.27 | 2021-2025 | Loreev Xr |
| Tris Pharma INC | $174.12 | 2020-2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $173.75 | 2019-2022 | |
| Bausch Health US, LLC | $136.28 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $132.71 | 2019-2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.88 | 2022-2025 | Caplyta |
| Alkermes, INC. | $61.42 | 2021-2022 | |
| Lundbeck LLC | $59.14 | 2019-2022 | |
| Axsome Therapeutics, INC. | $56.60 | 2022-2024 | Auvelity, Sunosi |
| Corium, LLC | $49.24 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $45.62 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $44.24 | 2020-2025 | Fanapt |
| Arbor Pharmaceuticals, INC. | $41.23 | 2019-2020 | |
| Neos Therapeutics, Lp | $31.50 | 2020-2022 | |
| Alfasigma USA, INC. | $13.73 | 2022 | |
| Allergan, INC. | $13.39 | 2020 | |
| Eisai INC. | $12.69 | 2022 | |
| Shire North American Group INC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Theresa Ladd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.